Pfizer (PFE) Stock Rises Ahead of Three-Day Review

Stock of the Day Newsletter -- 2/7/2005

Stock of the Day	Chart	Stock Analysis	Profile	Stock Research

Stock of the Day Pfizer (PFE) Pfizer Stock rises ahead of three-day review. Shares of Pfizer Inc., the world's largest drug maker, rose more than 2 percent on today ahead of an upcoming U.S. Food and Drug Administration meeting to review the risks and benefits of painkillers, including the company's own Celebrex. A panel of academic scientists are to meet to advise the U.S. Food and Drug Administration on the safety of Cox-2 inhibitors such as Celebrex, Bextra and the withdrawn Vioxx. They will also discuss the safety of older anti-inflammatory medicines such as Aleve and Motrin. The FDA has allotted three days for the work, a clear sign of controversy. Daily Chart If you are not able to see the chart, your email client probably does not support javascript. To view it, please click here Stock Analysis It will be an especially important meeting for Pfizer, which makes Celebrex and Bextra. The meeting is likely to determine the future of those drugs, if any. The discussion may also have an impact on Pfizer's potential liability. Even if Celebrex and Bextra don't make it through the meeting, Pfizer could look like a winner to investors as long as it doesn't face a massive liability cloud like the ever-ballooning diet-drug litigation that has weighed on smaller rival Wyeth for years. Buy Pfizer for just $4 Pfizer told drug regulators that its analysis of 41 of its own patient trials involving more than 40,000 patients found no evidence that Celebrex increased heart problems. Celebrex is one of Pfizer's best-selling medications, with $3.3 billion in sales last year. Pfizer's analysis was included in documents the FDA released this past Friday for public viewing ahead of the three-day hearings. Make Pfizer your first of 30 commission free trades when you join Ameritrade Shares of Pfizer gained notably on Monday following news that the company has told U.S. regulatory officials that all of its in-house clinical studies show its pain reliever Celebrex is safe. Pfizer shares were up 2.77 percent to $24.90 in trade Monday morning. Pfizer's stock rose 65 cents to $24.88 during afternoon trading on the New York Stock Exchange. Shares of Pfizer fell to $23.52 December 17 when concerns about Celebrex's risks appeared. The stock rose to more than $27 at the start of 2005, but has moved steadily lower to $23.80 on February 1st. Special Offers Buy PFE for just $4 Brown|Co. PFE $5 trades! Profile Pfizer Inc is a research-based, global pharmaceutical company that discovers and develops innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. Pfizer has three business segments: health care, animal health and consumer health care. Its products are available in numerous countries.			Our Sites WiserAdvisor InvestorGuide InvestorWords WebFinance Consulting Market Overview (As of 4.00 PM EST) DJIA 10,714.43 -1.70 S&P 1,201.28 -1.75 NASDAQ 2,079.84 -6.82 10Yr 4.052% -0.02 More market statistics Other Stocks Research Enter Ticker:  Most Viewed:  SIRI, BEBE, AOL, HON, MSO Your personal research page Enter Schwab Active Trader. Get 30 commission free trades. www.schwabat.com Buy Pfizer for just $4 www.sharebuilder.com Options Trading Hammered by the market? Protect your portfolio with options! www.optionsxpress.com Brown|Co. Trade Pfizer your way. Get $5 trades and low margin rates. No hidden fees. Apply now. www.brownco3.com Last 5 Stock of the Day Newsletters Starbucks (SBUX) MCI (MCIP) THQ (THQI) American Express (AXP) Eastman Kodak (EK) See the Complete Archive Here!

Additional Specific Research on Pfizer
Quote	Quote History	Monthly Chart If you are not able to see the chart, your email client probably does not support javascript. To view it, please click here
Profile	News
Charts	Option Chains
Stock Actions	Financials
Earnings	Short Interest
Insider Trading	Institutional Holdings
SEC Filings	Guru Analysis
Analyst Picks	Sector Comparison
Discussion	Search

Add PFE to your watch list

View your watch list


Today's other hot stocks:
SIRI
BEBE
AOL
HON
MSO





We encourage you to forward this FREE newsletter to your friends!
If you were forwarded this newsletter and wish to subscribe, click here.
If you have any comments/feedback about this newsletter, click here.

More links to important investing resources
InvestorWords Glossary With over 6,000 definitions, InvestorWords is the most comprehensive financial glossary available on the web and has helped millions of individuals understand today's financial world.		InvestorGuide University Not your typical university, InvestorGuide's educational section makes learning easy with easy-to-follow descriptions of important topics regarding investments and personal finance.		Our Other Newsletters The InvestorGuide Weekly summarizes important financial news and commentary of the past week, and the InvestorWords Term of the Day provides one complete and clear financial term definition per day.

Copyright 2005 by Investorguide.com, Inc. Investorguide has no control over the sites we link to, is not affiliated with these sites, and cannot take responsibility for their quality or suitability. The news, analysis, commentary and profile information is not meant to be comprehensive, and the data provided is not guaranteed to be accurate. WebFinance Inc., the publisher of this newsletter, is not a registered investment advisor or a broker/dealer. This is not a stock recommendation newsletter but rather a source for investment ideas, and we encourage you to fully research any company before considering investing. One WebFinance employee other than the author of this issue owns shares in the company described above. The above is neither an offer nor solicitation to buy or sell any securities. The trading of securities may not be suitable for all potential readers of this newsletter, and the purchase of stocks mentioned in this newsletter may result in the loss of some or all of any investment made. We recommend that you consult a stockbroker or financial advisor before buying or selling securities or making investment decisions. We are not responsible for claims made by advertisers and sponsors. Anyone who makes decisions based on what they read here does so at their own risk and cannot hold WebFinance Inc. (DBA Investorguide.com, Inc.) or its employees responsible.

To unsubscribe or change your subscription preferences
click here
Or send a message to investor.15@remove.mb00.net


For the complete disclaimer please href=http://www.investorguide.com/disclaimer1.html>click here

This message was sent to derevo.mail@blogger.com

pmguid:..